The Global Cardiopulmonary Autotransfusion Devices Market size was valued at $1.82 billion in 2019 and is projected to reach a value of $2.62 billion by 2028, at a CAGR of 5%. The on-pump transfusion device segment will lead the market with a share of 32% and an estimated value of $890 million by 2028. The factors driving growth in this market are the increasing incidence of cardiovascular diseases, the growing adoption rate of minimally invasive procedures, and technological advancements in medical equipment.
A Cardiopulmonary Autotransfusion device is a medical device that provides blood circulation from the donor to the recipient. Cardiopulmonary autotransfusion devices are used to perform cardiopulmonary bypass in cardiac surgery procedures. They work by giving a patient an oxygen-rich blood supply, which is then drained of carbon dioxide and saturates the tissues with nutrients and other substances that will eventually be needed for healing.
On the basis of Type, the market is segmented into On-Pump Transfusion Device and Off-Pump Transfusion Device. The on-pump transfusion device accounted for the largest share owing to its ease of use, which is a key factor in choosing this type.
An on-pump transfusion device is a kind of cardiopulmonary autotransfusion (CPAT) device that inverts the blood flow pattern. It is considered as an artificial heart and lungs, but it does not have its own pumping system. Instead, what makes it possible for CPAT to work are the external pumps which can be connected through tubes or hoses. This pump forces oxygenated blood from the right ventricle into both atria and returns it back to the left ventricle which then sends this now deoxygenated blood onto the rest of the body via systemic circulation.
Off-Pump Transfusion Devices are devices used for blood transfusions in patients who have been taken off cardiopulmonary bypass, but still, need a continuous flow of blood. Off-pump transcutaneous and percussive circulatory assist systems (PCAS) provide this support when the heart stops pumping on its own or is too weak to do so adequately enough.
The PCAS provides cardiac output by creating an artificial heartbeat with gentle vibrations that doesn’t overwork the patient’s remaining myocardium or cause clotting in their lower body circulation like a mechanical pump does. This type of device may be necessary for critically ill patients who rely solely on cardiopulmonary bypass during surgery.
On the basis of Application, the market is segmented into Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers. The market for application in hospitals is expected to grow at the fastest rate during the forecast period on account of their rising adoption.
Cardiopulmonary Autotransfusion is used in hospitals as a life-saving procedure to provide blood in emergency situations when there is a shortage. Cardiopulmonary Autotransfusion is used as an alternative for patients with injuries or diseases that prevent the patient from undergoing regular surgery, who need an organ transplant, or whose major organs are failing and cannot be replaced by conventional means. These include trauma victims; people needing kidney transplants; those awaiting other surgeries such as liver replacement because of complications caused by cirrhosis.
The use of Cardiopulmonary Autotransfusion devices in the ambulatory surgical centers market is expected to grow significantly, which will drive the growth for this segment during the forecast period. The high adoption rate and rising incidence rates of cardiovascular diseases such as hypertension are likely to increase demand for cardiopulmonary autotransfusion devices in hospitals across all regions during the forecast period.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The North American market accounted for a major share of the global market in 2017. The U.S., Canada, and Mexico are some of the major contributors to this regional segmentation. In the Asia Pacific, Japan is one of the largest markets which posted considerable growth rates during 2016-2017. China has also been an attractive destination for many manufacturers due to its increasing demand for cardiopulmonary devices.
The Latin American region had achieved remarkable development as Brazil was predicted to be among the top five countries with the highest CPD sales volume by 2020. Europe accounted for about 15% of the total market size and expected to dominate over other regions until 2028 owing to technological innovations coming up from various European vendors.
Despite the global economic slowdown, the cardiopulmonary autotransfusion devices market is expected to grow during 2021-2028 because of the increasing incidence of cardiac diseases and the high demand for blood transfusions in emerging economies such as China, India, and Brazil. Additionally, increased awareness about self-donation by promoting user-friendly donation methods will also drive the growth of the market during the forecast period. Furthermore, rising prevalence rates for chronic pulmonary conditions like COPD could lead to additional usage among patients with a low respiratory reserve who are unable to tolerate conventional oxygen therapy or mechanical ventilation on their own behalf; hence it would provide them access to manual chest compressions that can be performed even outside hospital setting without any support.
Up Market Research published a new report titled “Cardiopulmonary Autotransfusion Devices Market research report which is segmented by Types (On-Pump Transfusion Device, Off-Pump Transfusion Device), By Applications (Hospitals, Ambulatory Surgical Center, Cardiac Research Centers), By Players/Companies Fresenius Kabi, Haemonetics, LivaNova, Medtronic, Terumo, Stryker, Atrium Medical”.
|Report Attributes||Report Details|
|Report Title||Cardiopulmonary Autotransfusion Devices Market Research Report|
|By Type||On-Pump Transfusion Device, Off-Pump Transfusion Device|
|By Application||Hospitals, Ambulatory Surgical Center, Cardiac Research Centers|
|By Companies||Fresenius Kabi, Haemonetics, LivaNova, Medtronic, Terumo, Stryker, Atrium Medical|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||200|
|Number of Tables & Figures||140|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type On-Pump Transfusion Device, Off-Pump Transfusion Device and By Application Hospitals, Ambulatory Surgical Center, Cardiac Research Centers.
Some of the companies that are profiled in this report are:
Cardiopulmonary Autotransfusion Devices Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Cardiopulmonary Autotransfusion Devices Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Cardiopulmonary Autotransfusion Devices Market Report:
Some other reports from this category!